AUM Biosciences

    OverviewSuggest Edit

    AUM Biosciences is an oncology-focused biotechnology company. It develops highly selective targeted oncology therapeutics for the treatment of hepatocellular carcinoma, head and neck cancer, gastric cancer, cholangiocarcinoma, triple-negative breast cancer, as well as prostate and colorectal cancer.
    TypePrivate
    Founded2018
    HQSingapore, SG
    Websiteaumbiosciences.com

    Latest Updates

    Employees (est.) (Aug 2022)18
    Cybersecurity ratingBMore
    Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
    Banner background

    Key People/Management at AUM Biosciences

    John Patava

    John Patava

    Chief Operating Officer
    James Cornwall

    James Cornwall

    Chief Bussiness Officer
    Harish Dave

    Harish Dave

    Co-Founder, Chief Medical Officer
    Show more

    AUM Biosciences Office Locations

    AUM Biosciences has offices in Singapore, Wilmington and Collingwood
    Singapore, SG (HQ)
    7 Straits View, Marina One East Tower, #05-01
    Singapore, SG
    10 Anson Rd, 24 16a b International Plaza
    Collingwood, AU
    8 Gipps St
    Wilmington, DE, US
    251 Little Falls Dr
    Show all (4)

    AUM Biosciences Financials and Metrics

    Summary Metrics

    Founding Date

    2018

    AUM Biosciences Cybersecurity Score

    Cybersecurity ratingPremium dataset

    B

    82/100

    SecurityScorecard logo

    AUM Biosciences Online and Social Media Presence

    Embed Graph

    AUM Biosciences News and Updates

    AUM Biosciences Enters into Collaboration with Roche for Clinical Development of AUM001 in Combination with anti-PD-L1 Therapy in Solid Tumor Indications

    SINGAPORE and BETHESDA, MD, May 10, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences, a global clinical-stage biotech company focused on discovering and developing novel targeted oncology therapies, today announced that it has entered into a clinical trial collaboration and supply agreement with Roche to …

    AUM Biosciences Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate AUM001 in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer

    Plan to conduct a global Phase 2 clinical trial to evaluate MNK inhibitor (AUM001) in combination with MSD’s anti-PD-1 therapy KEYTRUDA for the treatment of MSS colorectal cancer Plan to conduct a global Phase 2 clinical trial to evaluate MNK inhibitor (AUM001) in combination with MSD’s anti-PD-1 th…

    AUM Biosciences and HANDOK Presented Phase 1 Data for AUM-601 at ESMO Targeted Anticancer Therapies Congress 2022

    SINGAPORE and SEOUL, South Korea, April 19, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences, a global clinical-stage biotech company, focused on discovering and developing novel targeted oncology therapeutics, Handok Inc. [002390: KOSPI] (“Handok”), a leading innovation-driven pharmaceutical / healthcare…

    AUM Biosciences Frequently Asked Questions

    • When was AUM Biosciences founded?

      AUM Biosciences was founded in 2018.

    • Who are AUM Biosciences key executives?

      AUM Biosciences's key executives are John Patava, James Cornwall and Harish Dave.

    • How many employees does AUM Biosciences have?

      AUM Biosciences has 18 employees.

    • Who are AUM Biosciences competitors?

      Competitors of AUM Biosciences include Kyowa Kirin, Ethypharm and Biocon.

    • Where is AUM Biosciences headquarters?

      AUM Biosciences headquarters is located at 7 Straits View, Marina One East Tower, #05-01, Singapore.

    • Where are AUM Biosciences offices?

      AUM Biosciences has offices in Singapore, Wilmington and Collingwood.

    • How many offices does AUM Biosciences have?

      AUM Biosciences has 4 offices.